The past decade has seen the development and launch of many novel animal health products. This report looks at more than 20 new active ingredients that already have collective sales of over $1 billion – a figure set to more than double over the next ten years.

Profiles include: avilamycin; benazepril; cefquinome; ceftiofur; danofloxacin; diclazuril; doramectin; enalapril; enrofloxacin; fipronil; florfenicol; imidacloprid; lufenuron; melar-somine; meloxicam; milbemycin; moxidectin; nicergolene; semduramicin; sometribove; tilmicosin; and toltrazuril.

Each product profile contains information on:

• development and mode of action – details of discovery, licensing information, mechanism of action, and spectrum of activity
• commercialisation – outlining geographical launch patterns and in many cases featuring tables of launch dates, trade names and distributors in major markets
• marketing strategy – product characteristics being promoted in advertising, comparisons with competitor products and, where relevant, pricing strategies
• performance – how the products have sold in their major markets since launch
• future development and prospects – plans being made for future development and their potential impact on sales, including unexploited indications and novel delivery systems

PUBLISHED: MARCH 1997
REF: SR162E
PAGES: 130
PRICE: £285/$600/¥69,000

• Order this report.
• Request a catalogue.

© PJB Publications Ltd. 2000 All rights reserved.